Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Tennessee › Nashville
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Nashville, TN keessatti
Qorannoo 28 Kansaar Onnee Triple-Negative f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute (SCRI), Nashville
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Namoota walitti qabaa jiraQorannoo ilaalaa
- Vanderbilt University Medical Center, Nashville
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Namoota walitti qabaa jiraSadarkaa 3
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0111), Nashville
- fi 1 dabalataa
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon - Tennessee Oncology, Nashville
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- Nashville General, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Namoota walitti qabaa jira
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Los Angeles, CAQorannoo 27
- Boston, MAQorannoo 26
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Chicago, ILQorannoo 16
- Columbus, OHQorannoo 16
- Grand Rapids, MIQorannoo 15
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.